YOLFTbeta
Jiangsu GDK Biotechnology Co Ltd

Jiangsu GDK Biotechnology Co Ltd

688670 · SHG · Healthcare / Biotechnology

13.06CNY-0.31 (-2.32%)

Price History

Full chart

Market Stats

Previous Close13.37
Open13.48
Day Range12.96 – 13.55
52-Week Range12.50 – 31.20
Volume2.70M
Market Cap2.31B
P/E (TTM)0.00
Forward P/E0.00
EPS-1.54
Dividend Yield0.00%
Beta0.28
50-Day Avg16.41
200-Day Avg17.72

About

Jiangsu Gdk Biological Technology Co., Ltd engages in the research, development, production, and sale of human vaccines. It offers quadrivalent influenza virus split vaccines. The company human vaccine products are used for the prevention of various infectious diseases, including influenza, rabies, chickenpox, shingles, and pneumonia. Jiangsu Gdk Biological Technology Co., Ltd was founded in 2008 and is based in Taizhou, China.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Liangbin Zhang
  • Employees357
  • HeadquartersNo. 12 Yujin Road, Taizhou, China, 225300, China
  • Websitehttps://www.gdkbio.com

Leadership

  • Mr. Liangbin ZhangGM & Director · b. 1976
  • Mr. Qiang HuangFinancial Director & Accounting Supevisor · b. 1980
  • Mr. Jianguo XiaDeputy GM & Director · b. 1974
  • Mr. Jin ZhouSecretary to the Board · b. 1984
  • Mr. Guo Xiong TianDeputy General Manager · b. 1979
  • Mr. Jing Yu ZouDeputy General Manager · b. 1976

Financials

Income Statement

Currency: CNY2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue--67.15M589.10M392.27M318.49M134.59M80.80M113.23M
Growth (%)---+777.27%-33.41%-18.81%-57.74%-39.96%+40.13%
Cost of Revenue-2.02M13.04M76.47M114.52M87.41M86.29M51.87M40.22M
Gross Profit--2.02M54.11M512.63M277.75M231.07M48.30M28.93M113.23M
Gross Margin--80.59%87.02%70.81%72.55%35.89%35.80%100.00%
Operating Expense-39.34M85.30M300.89M193.79M182.14M122.99M143.22M305.41M
Operating Income-47.33M-41.36M-31.19M211.74M83.97M48.94M-74.69M-114.29M-192.18M
Operating Margin---46.45%35.94%21.41%15.37%-55.49%-141.45%-169.72%
EBITDA-25.26M-17.64M-4.93M246.38M121.93M79.48M-54.76M-85.32M-163.20M
EBITDA Margin---7.34%41.82%31.08%24.95%-40.69%-105.59%-144.13%
Net Income-32.66M-28.01M-19.04M154.98M82.46M41.54M-70.99M-93.50M-173.47M
Net Income Margin---28.35%26.31%21.02%13.04%-52.75%-115.72%-153.20%
R&D18.32M12.08M23.75M28.53M35.26M32.41M15.47M33.61M91.78M
R&D as % of Total Revenue--35.37%4.84%8.99%10.18%11.50%41.59%81.05%
Interest Expense3.24M2.66M3.02M9.64M9.85M1.31M1.94M1.61M1.28M
Interest Expense % of Total Revenue--4.50%1.64%2.51%0.41%1.44%2.00%1.13%

Balance Sheet

Currency: CNY2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets298.06M311.39M397.30M777.98M1.75B1.83B1.63B1.53B1.42B
Total Liabilities359.39M400.73M505.68M535.47M293.12M367.11M260.52M255.33M319.50M
Total Equity-61.33M-89.34M-108.38M242.50M1.46B1.46B1.37B1.28B1.10B
Cash229.90K3.67M7.55M88.01M36.69M174.73M70.44M83.42M84.19M
Total Debt30.00M30.00M56.91M296.75M10.01M42.04M64.06M47.63M-
Net Debt29.77M26.33M49.36M208.73M-26.68M-132.69M-6.39M-35.79M11.86M

Cash Flow

Currency: CNY2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-33.24M-35.48M-54.05M109.46M103.93M38.60M80.90M-131.39M-166.45M
Investing Cash Flow-44.85M-611.42K-24.42M-71.26M-996.39M112.70M-187.71M146.59M-
Financing Cash Flow77.77M39.53M82.34M42.27M841.14M-13.25M2.52M-18.03M-
Capital Expenditure33.89M6.22M21.12M40.81M386.39M168.18M54.00M38.48M34.97M
Free Cash Flow-67.12M-41.70M-75.17M68.65M-282.46M-129.58M26.90M-169.86M-201.42M
Dividends Paid2.23M4.57M3.16M8.44M9.85M44.00M17.60M1.63M1.26M
FCF to OCF201.95%117.53%139.08%62.72%-271.79%-335.75%33.25%129.28%121.01%
Dividend Paid to FCF-3.33%-10.95%-4.20%12.29%-3.49%-33.96%65.43%-0.96%-0.62%

Earnings

Report DateSep 30, 2021Dec 31, 2021Apr 29, 2022Aug 6, 2022Oct 28, 2022Apr 20, 2023Aug 2, 2023
EPS Estimate-------
EPS Actual1.00-0.14-0.02-0.120.590.29-0.01
Surprise-------
Timing------Pre-market

Key Statistics & Ratios

Market Cap2.31B
Enterprise Value2.26B
Trailing P/E0.00
Forward P/E0.00
Price / Sales20.93
Price / Book2.22
EPS-1.54
Book Value8.51
Revenue (TTM)110.27M
Gross Profit (TTM)45.70M
EBITDA-164.77M
Profit Margin-172.20%
Operating Margin-244525.59%
Return on Equity-16.61%
Return on Assets-8.47%
Shares Outstanding123.20M
Shares Float36.48M
Beta0.28
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Dividends

20231×
0.20May 26, 2023
20221×
0.36May 18, 2022

Stock Splits

  • May 26, 20231.4:1